Anti-inflammatory effects of exercise: role in diabetes and cardiovascular disease

European Journal of Clinical Investigation

Volumn 47, Issue 8, 2017, Pages 600-611

  Pedersen, Bente Klarlund ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Cardiovascular disease; cytokines; diabetes; exercise; heart failure; inflammation

Indexed keywords

INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 6; TUMOR NECROSIS FACTOR; C REACTIVE PROTEIN; CYTOKINE; IL6 PROTEIN, HUMAN;

ANTIINFLAMMATORY ACTIVITY; ATHEROSCLEROSIS; BODY COMPOSITION; CARDIOMETABOLIC RISK; CARDIOVASCULAR DISEASE; DIABETES MELLITUS; EXERCISE; GLUCOSE TOLERANCE; HEART FAILURE; HUMAN; INFLAMMATION; INSULIN RESISTANCE; INTRACELLULAR SIGNALING; MEDICAL LITERATURE; METABOLISM; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS ISLET BETA CELL; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; ABDOMINAL FAT; ADAPTATION; HEART MUSCLE ISCHEMIA; KINESIOTHERAPY; PATHOPHYSIOLOGY; PHYSIOLOGY; YIN-YANG;

ABDOMINAL FAT; ADAPTATION, PHYSIOLOGICAL; C-REACTIVE PROTEIN; CYTOKINES; DIABETES MELLITUS, TYPE 2; EXERCISE; EXERCISE THERAPY; HEART FAILURE; HUMANS; INFLAMMATION; INSULIN-SECRETING CELLS; INTERLEUKIN-1BETA; INTERLEUKIN-6; MYOCARDIAL ISCHEMIA; TUMOR NECROSIS FACTOR-ALPHA; YIN-YANG;

EID: 85025097126     PISSN: 00142972     EISSN: 13652362     Source Type: Journal    
DOI: 10.1111/eci.12781     Document Type: Review

References (153)

1. Pedersen BK. The Diseasome of Physical Inactivity- and the role of myokines in muscle-fat cross talk. J Physiol 2009;587:5559–68.
2. Shoelson SE, Lee J, Goldfine AB. Inflammation and insulin resistance. J Clin Invest 2006;116:1793–801.
3. Donath MY, Shoelson SE. Type 2 diabetes as an inflammatory disease. Nat Rev Immunol 2011;11:98–107.
4. Chawla A, Nguyen KD, Goh YP. Macrophage-mediated inflammation in metabolic disease. Nat Rev Immunol 2011;11:738–49.
5. Ouchi N, Parker JL, Lugus JJ, Walsh K. Adipokines in inflammation and metabolic disease. Nat Rev Immunol 2011;11:85–97.
6. Dick SA, Epelman S. Chronic Heart Failure and Inflammation: What Do We Really Know? Circ Res 2016;119:159–76.
7. Knudsen SH, Pedersen BK. Targeting Inflammation Through a Physical Active Lifestyle and Pharmaceuticals for the Treatment of Type 2 Diabetes. Curr Diab Rep 2015;15:82.
8. Karstoft K, Pedersen BK. Exercise and type 2 diabetes: focus on metabolism and inflammation. Immunol Cell Biol 2016;94:146–50.
9. Handschin C, Spiegelman BM. The role of exercise and PGC1alpha in inflammation and chronic disease. Nature 2008;454:463–9.
10. McInnes IB, Schett G. Cytokines in the pathogenesis of rheumatoid arthritis. Nat Rev Immunol 2007;7:429–42.
11. Benatti FB, Pedersen BK. Exercise as an anti-inflammatory therapy for rheumatic diseases-myokine regulation. Nat Rev Rheumatol 2015;11:86–97.
12. Sitia S, Atzeni F, Sarzi-Puttini P, Di Bello V, Tomasoni L, Delfino L et al. Cardiovascular involvement in systemic autoimmune diseases. Autoimmun Rev 2009;8:281–6.
13. Petersen AM, Pedersen BK. The anti-inflammatory effect of exercise. J Appl Physiol 2005;98:1154–62.
14. Cronin O, Keohane DM, Molloy MG, Shanahan F. The effect of exercise interventions on inflammatory biomarkers in healthy, physically inactive subjects: a systematic review. QJM 2017; [Epub ahead of print].
15. Meneses-Echavez JF, Correa-Bautista JE, Gonzalez-Jimenez E, Schmidt Rio-Valle J, Elkins MR, Lobelo F et al. The Effect of Exercise Training on Mediators of Inflammation in Breast Cancer Survivors: A Systematic Review with Meta-analysis. Cancer Epidemiol Biomarkers Prev 2016;25:1009–17.
16. Neefkes-Zonneveld CR, Bakkum AJ, Bishop NC, van Tulder MW, Janssen TW. Effect of long-term physical activity and acute exercise on markers of systemic inflammation in persons with chronic spinal cord injury: a systematic review. Arch Phys Med Rehabil 2015;96:30–42.
17. Ryan SM, Kelly AM. Exercise as a pro-cognitive, pro-neurogenic and anti-inflammatory intervention in transgenic mouse models of Alzheimer's disease. Ageing Res Rev 2016;27:77–92.
18. Codella R, Luzi L, Inverardi L, Ricordi C. The anti-inflammatory effects of exercise in the syndromic thread of diabetes and autoimmunity. Eur Rev Med Pharmacol Sci 2015;19:3709–22.
19. Joseph MF, Denegar CR. Treating tendinopathy: perspective on anti-inflammatory intervention and therapeutic exercise. Clin Sports Med 2015;34:363–74.
20. Booth FW, Roberts CK, Laye MJ. Lack of exercise is a major cause of chronic diseases. Compr Physiol 2012;2:1143–211.
21. Pedersen BK, Saltin B. Exercise as medicine - evidence for prescribing exercise as therapy in 26 different chronic diseases. Scand J Med Sci Sports 2015;25(Suppl 3):1–72.
22. Pedersen BK. Exercise-induced myokines and their role in chronic diseases. Brain Behav Immun 2011;25:811–6.
23. Pedersen BK. Muscle as a secretory organ. Compr Physiol 2013;3:1337–62.
24. Trayhurn P, Drevon CA, Eckel J. Secreted proteins from adipose tissue and skeletal muscle - adipokines, myokines and adipose/muscle cross-talk. Arch Physiol Biochem 2011;117:47–56.
25. Whitham M, Febbraio MA. The ever-expanding myokinome: discovery challenges and therapeutic implications. Nat Rev Drug Discov 2016;15:719–29.
26. Hoffmann C, Weigert C. Skeletal Muscle as an Endocrine Organ: The Role of Myokines in Exercise Adaptations. Cold Spring Harb Perspect Med 2017;a029793. [Epub ahead of print].
27. Lucia A, Ramirez M. Muscling In on Cancer. N Engl J Med 2016;375:892–4.
28. Pedersen L, Idron M, Olofssen GH, Lauenborg B, Nookaew I, Hansen RH et al. Voluntary running suppresses tumor growth through epinephrine- and IL-6-dependent NK cell mobilization and redistribution. Cell Metab 2016;23:554–62.
29. Pedersen BK, Febbraio MA. Muscle as an Endocrine Organ: Focus on Muscle-Derived Interleukin-6. Physiol Rev 2008;88:1379–406.
30. Ostrowski K, Hermann C, Bangash A, Schjerling P, Nielsen JN, Pedersen BK. A trauma-like elevation of plasma cytokines in humans in response to treadmill running. J Physiol 1998;513(Pt 3):889–94.
31. Ostrowski K, Rohde T, Asp S, Schjerling P, Pedersen BK. Pro- and anti-inflammatory cytokine balance in strenuous exercise in humans. J Physiol 1999;515(Pt 1):287–91.
32. Ostrowski K, Schjerling P, Pedersen BK. Physical activity and plasma interleukin-6 in humans - effect of intensity of exercise. Eur J Appl Physiol 2000;83:512–5.
33. Fischer CP, Hiscock N, Basu S, Vessby B, Kallner A, Sjöberg LB et al. Supplementation with vitamins C and E inhibits the release of interleukin-6 from contracting human skeletal muscle. J Physiol 2004;558:633–45.
34. Steensberg A, van Hall G, Osada T, Sacchetti M, Saltin B, Klarlund PB. Production of interleukin-6 in contracting human skeletal muscles can account for the exercise-induced increase in plasma interleukin-6. J Physiol 2000;529(Pt 1):237–42.
35. Bergfors M, Barnekow-Bergkvist M, Kalezic N, Lyskov E, Eriksson JW. Short-term effects of repetitive arm work and dynamic exercise on glucose metabolism and insulin sensitivity. Acta Physiol Scand 2005;183:345–56.
36. Hirose L, Nosaka K, Newton M, Laveder A, Kano M, Peake J et al. Changes in inflammatory mediators following eccentric exercise of the elbow flexors. Exerc Immunol Rev 2004;10:75–90.
37. Nosaka K, Clarkson PM. Changes in indicators of inflammation after eccentric exercise of the elbow flexors. Med Sci Sports Exerc 1996;28:953–61.
38. Fischer CP. Interleukin-6 in acute exercise and training: What is the biological relevance? Exerc Immunol Rev 2006;12:6–33.
39. Keller C, Steensberg A, Pilegaard H, Osada T, Saltin B, Pedersen BK et al. Transcriptional activation of the IL-6 gene in human contracting skeletal muscle: influence of muscle glycogen content. FASEB J 2001;15:2748–50.
40. Steensberg A, Febbraio MA, Osada T, Schjerling P, van Hall G, Saltin B et al. Interleukin-6 production in contracting human skeletal muscle is influenced by pre-exercise muscle glycogen content. J Physiol (London) 2001;537(Pt 2):633–9.
41. Li TL, Gleeson M. The effects of carbohydrate supplementation during the second of two prolonged cycling bouts on immunoendocrine responses. Eur J Appl Physiol 2005;95:391–9.
42. Li TL, Gleeson M. The effect of single and repeated bouts of prolonged cycling on leukocyte redistribution, neutrophil degranulation, IL-6, and plasma stress hormone responses. Int J Sport Nutr Exerc Metab 2004;14:501–16.
43. Li TL, Wu CL, Gleeson M, Williams C. The effects of pre-exercise high carbohydrate meals with different glycemic indices on blood leukocyte redistribution, IL-6, and hormonal responses during a subsequent prolonged exercise. Int J Sport Nutr Exerc Metab 2004;14:647–56.
44. Lancaster GI, Jentjens RL, Moseley L, Jeukendrup AE, Gleeson M. Effect of pre-exercise carbohydrate ingestion on plasma cytokine, stress hormone, and neutrophil degranulation responses to continuous, high-intensity exercise. Int J Sport Nutr Exerc Metab 2003;13:436–53.
45. Nehlsen-Canarella SL, Fagoaga OR, Nieman DC, Henson DA, Butterworth DE, Schmitt RL et al. Carbohydrate and the cytokine response to 2.5 h of running. J Appl Physiol 1997;82:1662–7.
46. Henson DA, Nieman DC, Nehlsen-Cannarella SL, Fagoaga OR, Shannon M, Bolton MR et al. Influence of carbohydrate on cytokine and phagocytic responses to 2 h of rowing. Med Sci Sports Exerc 2000;32:1384–9.
47. Nieman DC, Nehlsen-Canarella SL, Fagoaga OR, Henson DA, Utter A, Davis JM et al. Influence of mode and carbohydrate on the cytokine response to heavy exertion. Med Sci Sports Exerc 1998;30:671–8.
48. Nieman DC, Davis JM, Henson DA, Walberg-Rankin J, Shute M, Dumke CL et al. Carbohydrate ingestion influences skeletal muscle cytokine mRNA and plasma cytokine levels after a 3-h run. J Appl Physiol 2003;94:1917–25.
49. Nieman DC, Davis JM, Henson DA, Gross SJ, Dumke CL, Utter AC et al. Muscle cytokine mRNA changes after 2.5 h of cycling: influence of carbohydrate. Med Sci Sports Exerc 2005;37:1283–90.
50. Nieman DC, Davis JM, Brown VA, Henson DA, Dumke CL, Utter AC et al. Influence of carbohydrate ingestion on immune changes after 2 h of intensive resistance training. J Appl Physiol 2004;96:1292–8.
51. Steensberg A, Fischer CP, Keller C, Moller K, Pedersen BK. IL-6 enhances plasma IL-1ra, IL-10, and cortisol in humans. Am J Physiol Endocrinol Metab 2003;285:E433–7.
52. Dinarello CA. The interleukin-1 family: 10 years of discovery. FASEB J 1994;8:1314–25.
53. Opp MR, Smith EM, Hughes TK Jr. Interleukin-10 (cytokine synthesis inhibitory factor) acts in the central nervous system of rats to reduce sleep. J Neuroimmunol 1995;60:165–8.
54. Starkie R, Ostrowski SR, Jauffred S, Febbraio M, Pedersen BK. Exercise and IL-6 infusion inhibit endotoxin-induced TNF-alpha production in humans. FASEB J 2003;17:884–6.
55. Schindler R, Mancilla J, Endres S, Ghorbani R, Clark SC, Dinarello CA. Correlations and interactions in the production of interleukin-6 (IL-6), IL-1, and tumor necrosis factor (TNF) in human blood mononuclear cells: IL-6 suppresses IL-1 and TNF. Blood 1990;75:40–7.
56. Mizuhara H, O'Neill E, Seki N, Ogawa T, Kusunoki C, Otsuka K et al. T cell activation-associated hepatic injury: mediation by tumor necrosis factors and protection by interleukin 6. J Exp Med 1994;179:1529–37.
57. van der Poll T, Coyle SM, Barbosa K, Braxton CC, Lowry SF. Epinephrine inhibits tumor necrosis factor-alpha and potentiates interleukin 10 production during human endotoxemia. J Clin Invest 1996;97:713–9.
58. Nieman DC, Fagoaga OR, Butterworth DE, Warren BJ, Utter A, Davis JM et al. Carbohydrate supplementation affects blood granulocyte and monocyte trafficking but not function after 2.5 h or running. Am J Clin Nutr 1997;66:153–9.
59. Pischon T, Boeing H, Hoffmann K, Bergmann M, Schulze MB, Overvad K et al. General and Abdominal Adiposity and Risk of Death in Europe. New Engl J Med 2008;359:2105–20.
60. Yudkin JS. Inflammation, obesity, and the metabolic syndrome. Horm Metab Res 2007;39:707–9.
61. Laye MJ, Thyfault JP, Stump CS, Booth FW. Inactivity induces increases in abdominal fat. J Appl Physiol 2007;102:1341–7.
62. Olsen RH, Krogh-Madsen R, Thomsen C, Booth FW, Pedersen BK. Metabolic responses to reduced daily steps in healthy nonexercising men. JAMA 2008;299:1261–3.
63. Krogh-Madsen R, Pedersen M, Solomon TP, Knudsen SH, Hansen LS, Karstoft K et al. Normal physical activity obliterates the deleterious effects of a high-caloric intake. J Appl Physiol (1985) 2014;116:231–9.
64. Krogh-Madsen R, Thyfault JP, Broholm C, Mortensen OH, Olsen RH, Mounier R et al. A 2-wk reduction of ambulatory activity attenuates peripheral insulin sensitivity. J Appl Physiol 2010;108:1034–40.
65. Harder-Lauridsen NM, Nielsen ST, Mann SP, Lyngbaek MP, Benatti FB, Langkilde AR et al. The effect of alternate-day caloric restriction on the metabolic consequences of 8 days of bed rest in healthy lean men: a randomized trial. J Appl Physiol (1985) 2017;122:230–41.
66. Knudsen SH, Hansen LS, Pedersen M, Dejgaard T, Hansen J, Hall GV et al. Changes in insulin sensitivity precede changes in body composition during 14 days of step reduction combined with overfeeding in healthy young men. J Appl Physiol 2012;113:7–15.
67. Rosenkilde M, Nordby P, Stallknecht B. Maintenance of improvements in fitness and fatness 1 year after a 3-month lifestyle intervention in overweight men. Eur J Clin Nutr 2016;70:1212–4.
68. Rinnov A, Yfanti C, Nielsen S, Akerstrom TC, Peijs L, Zankari A et al. Endurance training enhances skeletal muscle interleukin-15 in human male subjects. Endocrine 2014;45:271–8.
69. Grabstein KH, Eisenman J, Shanebeck K, Rauch C, Srinivasan S, Fung V et al. Cloning of a T cell growth factor that interacts with the beta chain of the interleukin-2 receptor. Science 1994;264:965–8.
70. Furmanczyk PS, Quinn LS. Interleukin-15 increases myosin accretion in human skeletal myogenic cultures. Cell Biol Int 2003;27:845–51.
71. Quinn LS, Haugk KL, Damon SE. Interleukin-15 stimulates C2 skeletal myoblast differentiation. Biochem Biophys Res Commun 1997;239:6–10.
72. Quinn LS, Haugk KL, Grabstein KH. Interleukin-15: a novel anabolic cytokine for skeletal muscle. Endocrinology 1995;136:3669–72.
73. Nielsen AR, Hojman P, Erikstrup C, Fischer CP, Plomgaard P, Mounier R et al. Association between IL-15 and obesity: IL-15 as a potential regulator of fat mass. J Clin Endocrinol Metab 2008;93:4486–93.
74. Carbo N, Lopez-Soriano J, Costelli P, Alvarez B, Busquets S, Baccino FM et al. Interleukin-15 mediates reciprocal regulation of adipose and muscle mass: a potential role in body weight control. Biochim Biophys Acta 2001;1526:17–24.
75. Quinn LS, Strait-Bodey L, Anderson BG, Argiles JM, Havel PJ. Interleukin-15 stimulates adiponectin secretion by 3T3-L1 adipocytes: evidence for a skeletal muscle-to-fat signaling pathway. Cell Biol Int 2005;29:449–57.
76. Sanchez-Jimenez R, Alvarado-Vasquez N. IL-15 that a regulator of TNF-alpha in patients with diabetes mellitus type 2. Med Hypotheses 2013;80:776–7.
77. van Hall G, Steensberg A, Sacchetti M, Fischer C, Keller C, Schjerling P et al. Interleukin-6 stimulates lipolysis and fat oxidation in humans. J Clin Endocrinol Metab 2003;88:3005–10.
78. Ruderman NB, Keller C, Richard AM, Saha AK, Luo Z, Xiang X et al. Interleukin-6 regulation of AMP-activated protein kinase: potential role in the systemic response to exercise and prevention of the metabolic syndrome. Diabetes 2006;55(Suppl 2):S48–54.
79. Pedersen BK, Pedersen M, Krabbe KS, Bruunsgaard H, Matthews VB, Febbraio MA. Role of exercise-induced brain-derived neurotrophic factor production in the regulation of energy homeostasis in mammals. Exp Physiol 2009;94:1153–60.
80. Pickup JC, Mattock MB, Chusney GD, Burt D. NIDDM as a disease of the innate immune system: association of acute- phase reactants and interleukin-6 with metabolic syndrome X. Diabetologia 1997;40:1286–92.
81. Spranger J, Kroke A, Mohlig M, Hoffmann K, Bergmann MM, Ristow M et al. Inflammatory Cytokines and the Risk to Develop Type 2 Diabetes: Results of the Prospective Population-Based European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam Study. Diabetes 2003;52:812–7.
82. Herder C, Illig T, Rathmann W, Martin S, Haastert B, Muller-Scholze S et al. Inflammation and type 2 diabetes: results from KORA Augsburg. Gesundheitswesen 2005;67(Suppl 1):S115–21.
83. Herder C, Brunner EJ, Rathmann W, Strassburger K, Tabak AG, Schloot NC et al. Elevated levels of the anti-inflammatory interleukin-1 receptor antagonist precede the onset of type 2 diabetes: the Whitehall II study. Diabetes Care 2009;32:421–3.
84. Pedersen M, Bruunsgaard H, Weis N, Hendel HW, Andreassen BU, Eldrup E et al. Circulating levels of TNF-alpha and IL-6-relation to truncal fat mass and muscle mass in healthy elderly individuals and in patients with type-2 diabetes. Mech Ageing Dev 2003;124:495–502.
85. Plomgaard P, Nielsen AR, Fischer CP, Mortensen OH, Broholm C, Penkowa M et al. Associations between insulin resistance and TNF-alpha in plasma, skeletal muscle and adipose tissue in humans with and without type 2 diabetes. Diabetologia 2007;50:2562–71.
86. Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA 2001;286:327–34.
87. Carstensen M, Herder C, Kivimaki M, Jokela M, Roden M, Shipley MJ et al. Accelerated increase in serum interleukin-1 receptor antagonist starts 6 years before diagnosis of type 2 diabetes: Whitehall II prospective cohort study. Diabetes 2010;59:1222–7.
88. Eguchi K, Manabe I. Macrophages and islet inflammation in type 2 diabetes. Diabetes Obes Metab 2013;15(Suppl 3):152–8.
89. Ehses JA, Perren A, Eppler E, Ribaux P, Pospisilik JA, Maor-Cahn R et al. Increased number of islet-associated macrophages in type 2 diabetes. Diabetes 2007;56:2356–70.
90. Westwell-Roper CY, Ehses JA, Verchere CB. Resident macrophages mediate islet amyloid polypeptide-induced islet IL-1beta production and beta-cell dysfunction. Diabetes 2014;63:1698–711.
91. Alluisi EA, Beisel WR, Morgan BB Jr, Caldwell LS. Effects of sandfly fever on isometric muscular strength, endurance, and recovery. J Mot Behav 1980;12:1–11.
92. Cabrera SM, Wang X, Chen YG, Jia S, Kaldunski ML, Greenbaum CJ et al. Interleukin-1 antagonism moderates the inflammatory state associated with Type 1 diabetes during clinical trials conducted at disease onset. Eur J Immunol 2016;46:1030–46.
93. Urwyler SA, Schuetz P, Ebrahimi F, Donath MY, Christ-Crain M. Interleukin-1 Antagonism Decreases Cortisol Levels in Obese Individuals. J Clin Endocrinol Metab 2017;102:1712–8.
94. Dror E, Dalmas E, Meier DT, Wueest S, Thevenet J, Thienel C et al. Postprandial macrophage-derived IL-1beta stimulates insulin, and both synergistically promote glucose disposal and inflammation. Nat Immunol 2017;18:283–92.
95. Hotamisligil GS, Peraldi P, Budavari A, Ellis R, White MF, Spiegelman BM. IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-alpha- and obesity-induced insulin resistance. Science 1996;271:665–8.
96. Uysal KT, Wiesbrock SM, Marino MW, Hotamisligil GS. Protection from obesity-induced insulin resistance in mice lacking TNF-alpha function. Nature 1997;389:610–4.
97. Plomgaard P, Bouzakri K, Krogh-Madsen R, Mittendorfer B, Zierath JR, Pedersen BK. Tumor necrosis factor-alpha induces skeletal muscle insulin resistance in healthy human subjects via inhibition of Akt substrate 160 phosphorylation. Diabetes 2005;54:2939–45.
98. Bouzakri K, Plomgaard P, Berney T, Donath MY, Pedersen BK, Halban PA. Bimodal effect on pancreatic â-cells of secretory products from normal or insulin-resistant human skeletal muscle. Diabetes 2011;60:1111–21.
99. Wellen KE, Hotamisligil GS. Inflammation, stress, and diabetes. J Clin Invest 2005;115:1111–9.
100. Hotamisligil GS. Inflammation and endoplasmic reticulum stress in obesity and diabetes. Int J Obes (Lond) 2008;32(Suppl 7):S52–4.
101. Timper K, Denson JL, Steculorum SM, Heilinger C, Engstrom-Ruud L, Wunderlich CM et al. IL-6 Improves Energy and Glucose Homeostasis in Obesity via Enhanced Central IL-6 trans-Signaling. Cell Rep 2017;19:267–80.
102. van der Vusse GJ, Reneman RS. Lipid metabolism in muscle. In:Rowell LB, Shepherd JT, editors. Handbook of Physiology. New York, NY: Oxford University Press, 1996; pp. 952–94.
103. Hiscock N, Chan MH, Bisucci T, Darby IA, Febbraio MA. Skeletal myocytes are a source of interleukin-6 mRNA expression and protein release during contraction: evidence of fiber type specificity. FASEB J 2004;18:992–4.
104. King DS, Dalsky GP, Clutter WE, Young DA, Staten MA, Cryer PE et al. Effects of exercise and lack of exercise on insulin sensitivity and responsiveness. J Appl Physiol 1988;64:1942–6.
105. Kelly M, Keller C, Avilucea PR, Keller P, Luo Z, Xiang X et al. AMPK activity is diminished in tissues of the IL-6 knockout mice: the effect of exercise. Biochem Biophys Res Commun 2004;320:449–54.
106. Al-Khalili L, Bouzakri K, Glund S, Lonnqvist F, Koistinen HA, Krook A. Signaling specificity of interleukin-6 action on glucose and lipid metabolism in skeletal muscle. Mol Endocrinol 2006;20:3364–75.
107. Carey AL, Steinberg GR, Macaulay SL, Thomas WG, Holmes AG, Ramm G et al. IL-6 increases insulin stimulated glucose disposal in humans and glucose uptake and fatty acid oxidation in vitro via AMPK. Diabetes 2006;55:2688–97.
108. Glund S, Deshmukh A, Long YC, Moller T, Koistinen HA, Caidahl K et al. Interleukin-6 directly increases glucose metabolism in resting human skeletal muscle. Diabetes 2007;56:1630–7.
109. Fisher JS, Gao J, Han DH, Holloszy JO, Nolte LA. Activation of AMP kinase enhances sensitivity of muscle glucose transport to insulin. Am J Physiol Endocrinol Metab 2002;282:E18–23.
110. Jakobsen SN, Hardie DG, Morrice N, Tornqvist HE. 5’-AMP-activated protein kinase phosphorylates IRS-1 on Ser-789 in mouse C2C12 myotubes in response to 5-aminoimidazole-4-carboxamide riboside. J Biol Chem 2001;276:46912–6.
111. Bruce CR, Dyck DJ. Cytokine regulation of skeletal muscle fatty acid metabolism: effect of interleukin-6 and tumor necrosis factor-alpha. Am J Physiol Endocrinol Metab 2004;287:E616–21.
112. Petersen EW, Carey AL, Sacchetti M, Steinberg GR, Macaulay SL, Febbraio MA et al. Acute IL-6 treatment increases fatty acid turnover in elderly humans in vivo and in tissue culture in vitro: evidence that IL-6 acts independently of lipolytic hormones. Am J Physiol 2005;288:E155–62.
113. Wallenius V, Wallenius K, Ahren B, Rudling M, Carlsten H, Dickson SL et al. Interleukin-6-deficient mice develop mature-onset obesity. Nat Med 2002;8:75–9.
114. Ellingsgaard H, Ehses JA, Hammar EB, Van LL, Quintens R, Martens G et al. Interleukin-6 regulates pancreatic alpha-cell mass expansion. Proc Natl Acad Sci U S A 2008;105:13163–8.
115. Ellingsgaard H, Hauselmann I, Schuler B, Eppler E, Meier D, Bouzakri K et al. Interleukin-6 enhances insulin secretion by increasing glucagon-like peptide-1 secretion from L cells and alpha cells. Nat Med 2011;17:1481–9.
116. Timper K, Dalmas E, Dror E, Rutti S, Thienel C, Sauter NS et al. Glucose-Dependent Insulinotropic Peptide Stimulates Glucagon-Like Peptide 1 Production by Pancreatic Islets via Interleukin 6, Produced by alpha Cells. Gastroenterology 2016;151:165–79.
117. Braune J, Weyer U, Hobusch C, Mauer J, Bruning JC, Bechmann I et al. IL-6 Regulates M2 Polarization and Local Proliferation of Adipose Tissue Macrophages in Obesity. J Immunol 2017;198:2927–34.
118. Mauer J, Chaurasia B, Goldau J, Vogt MC, Ruud J, Nguyen KD et al. Signaling by IL-6 promotes alternative activation of macrophages to limit endotoxemia and obesity-associated resistance to insulin. Nat Immunol 2014;15:423–30.
119. Mauer J, Denson JL, Bruning JC. Versatile functions for IL-6 in metabolism and cancer. Trends Immunol 2015;36:92–101.
120. Brown WV, Remaley AT, Ridker PM. JCL Roundtable: is inflammation a future target in preventing arteriosclerotic cardiovascular disease. J Clin Lipidol 2015;9:119–28.
121. Ridker PM, Hennekens CH, Buring JE, Rifai NC. reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. New Engl J Med 2000;342:836–43.
122. Wilund KR. Is the anti-inflammatory effect of regular exercise responsible for reduced cardiovascular disease? Clin Sci (Lond) 2007;112:543–55.
123. Boa BC, Yudkin JS, van Hinsbergh VW, Bouskela E, Eringa EC. Exercise effects on perivascular adipose tissue: endocrine and paracrine determinants of vascular function. Br J Pharmacol 2017; [Epub ahead of print].
124. Meijer RI, Serne EH, Smulders YM, van Hinsbergh VW, Yudkin JS, Eringa EC. Perivascular adipose tissue and its role in type 2 diabetes and cardiovascular disease. Curr Diab Rep 2011;11:211–7.
125. Li JJ, Fang CH. C-reactive protein is not only an inflammatory marker but also a direct cause of cardiovascular diseases. Med Hypotheses 2004;62:499–506.
126. Van Lenten BJ, Wagner AC, Navab M, Fogelman AM. Oxidized phospholipids induce changes in hepatic paraoxonase and ApoJ but not monocyte chemoattractant protein-1 via interleukin-6. J Biol Chem 2001;276:1923–9.
127. Schieffer B, Selle T, Hilfiker A, Hilfiker-Kleiner D, Grote K, Tietge UJ et al. Impact of interleukin-6 on plaque development and morphology in experimental atherosclerosis. Circulation 2004;110:3493–500.
128. Tam LS, Kitas GD, Gonzalez-Gay MA. Can suppression of inflammation by anti-TNF prevent progression of subclinical atherosclerosis in inflammatory arthritis? Rheumatology (Oxford) 2014;53:1108–19.
129. McKellar GE, McCarey DW, Sattar N, McInnes IB. Role for TNF in atherosclerosis? Lessons from autoimmune disease. Nat Rev Cardiol 2009;6:410–7.
130. Rus HG, Niculescu F, Vlaicu R. Tumor necrosis factor-alpha in human arterial wall with atherosclerosis. Atherosclerosis 1991;89:247–54.
131. Couffinhal T, Duplaa C, Labat L, Lamaziere JM, Moreau C, Printseva O et al. Tumor necrosis factor-alpha stimulates ICAM-1 expression in human vascular smooth muscle cells. Arterioscler Thromb 1993;13:407–14.
132. Wyble CW, Hynes KL, Kuchibhotla J, Marcus BC, Hallahan D, Gewertz BL. TNF-alpha and IL-1 upregulate membrane-bound and soluble E-selectin through a common pathway. J Surg Res 1997;73:107–12.
133. Pedersen BK, Febbraio MA. Muscles, exercise and obesity: skeletal muscle as a secretory organ. Nat Rev Endocrinol 2012;8:457–65.
134. Khovidhunkit W, Memon RA, Feingold KR, Grunfeld C. Infection and inflammation-induced proatherogenic changes of lipoproteins. J Infect Dis 2000;181(Suppl 3):S462–72.
135. Vallance P, Collier J, Bhagat K. Infection, inflammation, and infarction: does acute endothelial dysfunction provide a link? Lancet 1997;349:1391–2.
136. Sattar N, McCarey DW, Capell H, McInnes IB. Explaining how “high-grade” systemic inflammation accelerates vascular risk in rheumatoid arthritis. Circulation 2003;108:2957–63.
137. Yudkin JS, Eringa E, Stehouwer CD. “Vasocrine” signalling from perivascular fat: a mechanism linking insulin resistance to vascular disease. Lancet 2005;365:1817–20.
138. Plomgaard P, Keller P, Keller C, Pedersen BK. TNF-alpha, but not IL-6, stimulates plasminogen activator inhibitor-1 expression in human subcutaneous adipose tissue. J Appl Physiol 2005;98:2019–23.
139. Angel K, Provan SA, Fagerhol MK, Mowinckel P, Kvien TK, Atar D. Effect of 1-year anti-TNF-alpha therapy on aortic stiffness, carotid atherosclerosis, and calprotectin in inflammatory arthropathies: a controlled study. Am J Hypertens 2012;25:644–50.
140. Mann DL. Innate immunity and the failing heart: the cytokine hypothesis revisited. Circ Res 2015;116:1254–68.
141. Bozkurt B, Kribbs SB, Clubb FJ Jr, Michael LH, Didenko VV, Hornsby PJ et al. Pathophysiologically relevant concentrations of tumor necrosis factor-alpha promote progressive left ventricular dysfunction and remodeling in rats. Circulation 1998;97:1382–91.
142. Diwan A, Dibbs Z, Nemoto S, DeFreitas G, Carabello BA, Sivasubramanian N et al. Targeted overexpression of noncleavable and secreted forms of tumor necrosis factor provokes disparate cardiac phenotypes. Circulation 2004;109:262–8.
143. Flesch M, Hoper A, Dell'Italia L, Evans K, Bond R, Peshock R et al. Activation and functional significance of the renin-angiotensin system in mice with cardiac restricted overexpression of tumor necrosis factor. Circulation 2003;108:598–604.
144. Deswal A, Bozkurt B, Seta Y, Parilti-Eiswirth S, Hayes FA, Blosch C et al. Safety and efficacy of a soluble P75 tumor necrosis factor receptor (Enbrel, etanercept) in patients with advanced heart failure. Circulation 1999;99:3224–6.
145. Bozkurt B, Torre-Amione G, Warren MS, Whitmore J, Soran OZ, Feldman AM et al. Results of targeted anti-tumor necrosis factor therapy with etanercept (ENBREL) in patients with advanced heart failure. Circulation 2001;103:1044–7.
146. Chung ES, Packer M, Lo KH, Fasanmade AA, Willerson JT. Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial. Circulation 2003;107:3133–40.
147. Plomgaard P, Fischer CP, Ibfelt T, Pedersen BK, van Hall G. Tumor necrosis factor-alpha modulates human in vivo lipolysis. J Clin Endocrinol Metab 2008;93:543–9.
148. Pedersen BK, Febbraio MA. Point: Interleukin-6 does have a beneficial role in insulin sensitivity and glucose homeostasis. J Appl Physiol 2007;102:814–6.
149. Munoz-Canoves P, Scheele C, Pedersen BK, Serrano AL. Interleukin-6 myokine signaling in skeletal muscle: a double-edged sword? FEBS J 2013;280:4131–48.
150. Analay Y, Ozcan E, Karan A, Diracoglu D, Aydin R. The effectiveness of intensive group exercise on patients with ankylosing spondylitis. Clin Rehabil 2003;17:631–6.
151. Pedersen BK. Muscular IL-6 and Its Role as an Energy Sensor. Med Sci Sports Exerc 2012;44:392–6.
152. Rosenvinge A, Krogh-Madsen R, Baslund B, Pedersen BK. Insulin resistance in patients with rheumatoid arthritis: effect of anti-TNFalpha therapy. Scand J Rheumatol 2007;36:91–6.
153. Moore SC, Patel AV, Matthews CE, de Berrington GA, Park Y, Katki HA et al. Leisure time physical activity of moderate to vigorous intensity and mortality: a large pooled cohort analysis. PLoS Med 2012;9:e1001335.